AtriCure, Inc. ATRC 深 沪
交易中 06-03 10:41:21 美东时间
25.85
-0.010
-0.04%
华盛通- 最 高26.63
- 今 开25.86
- 成交量 6.04万股
- 最 低 25.7201
- 昨 收 25.86
- 总市值 130.91万
- 52周最高 43.18
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 25.36
- 委 比 -25.00%
- 总股本 5.06万
- 历史最高 89.18
- 量 比 0.49
- 振 幅 3.52%
- 历史最低 5.90
- 每 手 1
- 风险率 4.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $55
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $53 to $55.
05-07 06:58
AtriCure Q1 2026 Earnings Call Transcript
AtriCure (NASDAQ:ATRC) reported first-quarter financial results on Tuesday. The...
05-06 05:33
AtriCure shares are trading higher after the company reported better-than-expected Q1 financial results.
AtriCure shares are trading higher after the company reported better-than-expec...
05-06 04:51
AtriCure Lowers FY2026 Adj EPS Guidance from $0.09-$0.15 to $0.00-$0.04 vs $0.07 Est; Affirms FY2026 Sales Guidance of $600.000M-$610.000M vs $604.053M Est
2026 Financial GuidanceFull year 2026 revenue is projected to be approximately $600 million to $610 million, and management also projects full year 2026 Adjusted EBITDA of approximately $80 million to $82 million.
05-06 04:04
AtriCure Q1 Adj. EPS $0.00 Beats $(0.06) Estimate, Sales $141.249M Beat $139.812M Estimate
AtriCure (NASDAQ:ATRC) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.06) by 100 percent. This is a 100 percent increase over losses of $(0.14) per share from the same
05-06 04:02
Earnings Scheduled For May 5, 2026
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
Oppenheimer Downgrades AtriCure to Perform
Oppenheimer analyst Suraj Kalia downgrades AtriCure (NASDAQ:ATRC) from Outperform to Perform.
02-18 19:39
电话会总结 ｜ AtriCure(ATRC)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据AtriCure业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 2025年全年总营收5.345亿美元，同比增长14.9%（按报告基准）和14.4%（按固定汇率基准） - 第四季度营收1.405亿美元，同比增长13.1%（按报告基准）和12.1%（按固定汇率基准） - 美国市场营收4.354亿美元，同比增长13.7% - 国际市场营收9920万美元，同比增长20.2%（按报告基准）和17.5%（按固定汇率基准） **盈利能力：** - 全年毛利率75%，较2024年提升29个基点 - 第四季度毛利率75%，较20
02-18 12:23
